DOCSLIB.ORG

52Nd Annual Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ACNP 52nd Annual Meeting Final Program December 8-12, 2013 The Westin Diplomat Resort & Spa Hollywood, Florida President: David A. Lewis, M.D. Program Committee Chair: Randy D. Blakely, Ph.D. Program Committee Co-Chair: Pat R. Levitt, Ph.D. This meeting is jointly sponsored by the Vanderbilt University School of Medicine Department of Psychiatry and the American College of Neuropsychopharmacology. Dear ACNP Members and Guests, It is a distinct pleasure to welcome you to the 2014 meeting of the American College of Neuropsychopharmacology! This 52nd annual meeting will again provide opportunities for the exercise of the College’s core values: the spirit of Collegiality, promoting in each other the best in science, training and service; participation in Community, pursuing together the goals of understanding the neurobiology of brain diseases and eliminating their burden on individuals and our society; and engaging in Celebration, taking the time to recognize and enjoy the contributions and accomplishments of our members and guests. Under the excellent leadership of Randy Blakely and Pat Levitt, the Program Committee has done a superb job in assembling an outstanding slate of scientific presentations. Based on membership feedback, the meeting schedule has been designed with the goals of achieving an optimal mix of topics and types of sessions, increasing the diversity of participating scientists and creating more time for informal interactions. The presentations will highlight both the breadth of the investigative interests of ACNP membership and the unprecedented depth of studies examining disease mechanisms and new strategies for treating these illnesses. Accordingly, the theme of this year’s meeting, reflected in the title of the Plenary Session, is “Neural Circuitry Structure and Plasticity: Substrate for Brain Disorders and Novel Therapeutics.” I believe you will experience at this meeting ample evidence of the continued efforts of ACNP Council and staff to ensure the College’s successful leadership in shaping the future of our field, in facilitating the engagement of a broader group of investigators and in preserving the distinctive features that define us as a unique community of scientists and clinicians. I would like to extend a special note of thanks to Ronnie Wilkins, Sarah Timm, Laura Bersacola-Hill and the rest of the ACNP staff for their tremendous help and good humor over the past year. It has been a pleasure and honor to serve as president of the ACNP. I hope you find the meeting enlightening, energizing and enjoyable! David A. Lewis, M.D. President, 2013 ACNP AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY 52nd ANNUAL MEETING GENERAL PROGRAM HOLLYWOOD, FLORIDA WESTIN DIPLOMAT RESORT & SPA DECEMBER 8-12, 2013 Disclosures for 2013 speakers (mini-panel, panel, study group, and plenary) and poster presenters may be found online at: www.acnp.org (click the Annual Meeting tab). Vanderbilt CME has determined that there is no conflict of interest. ACNP Annual Meeting Book 2013 rev8.indd 1 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program 2nd Floor Convention Center THE WESTIN CONVENTION SERVICE FREIGHT DIPLOMAT CENTER ELEVATORS ELEVATOR ATLANTIC REGENCY BALLROOM BALLROOM 54 3 3 GRAND GRAND ATLANTIC BALLROOM BALLROOM RRIDOR BALLROOM REGENCY RRIDOR DIPLOMAT EAST WEST CO 2 BALLROOM CO BALLROOM 2 3 VICE ATLANTIC VICE SER BALLROOM 1 REGENCY SER 1 2 BALLROOM M W 1 S REGISTRATION ESCALATOR ELEVATORS E W TERRACE N WALKWAY TO RESORT Meeting rooms for panels, mini-panels, plenaries, and study groups are on the 2nd floor of the Convention Center (map above). Poster sessions and group lunches are on the 3rd floor (map below). 3rd Floor Convention Center THE WESTIN CONVENTION SERVICE DIPLOMAT CENTER ELEVATORS FREIGHT ELEVATOR M W GREAT HALL GREAT HALL M 6 2 GREAT HALL GREAT HALL TERRACE 4 3 GREAT HALL GREAT HALL W 5 1 S ELEVATORS REGISTRATION E W N ESCALATOR ii ACNP Annual Meeting Book 2013 rev8.indd 2 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Resort, Second Floor THE WESTIN CONVENTION NORTH SOUTH DIPLOMAT CENTER TOWER TERRAC TOWER TERRACE E 203 218 202 201 220 219 204 217 ESCALATORS 205 216 SERVICE ELEVATORS SERVICE WALKWAY TO ELEVATORS ELEVATORS ELEVATORS SKYWALK CONVENTION CENTER MW 209 WM 206 208 215 E 207 212 213 214 N S EXECUTIVE BUSINESS OFFICES CENTER TERRACE W Conference rooms for committee and board meetings are located on the 2nd and 3rd floor of the hotel. Most small meetings have been scheduled on the hotel side. Resort, Third Floor THE WESTIN CONVENTION NORTH SOUTH TERRAC DIPLOMAT CENTER TOWER TOWER TERRACE E 318 302 301 320319 303 317 322 321 305 316 ESCALATOR ESCALATOR SERVICE ELEVATORS SERVICE ELEVATORS SKYWALK ELEVATORS ELEVATORS MW 309 310 WM 306 308 311 315 E 312 313 314 307 N S EXECUTIVE OFFICES TERRACE W iii ACNP Annual Meeting Book 2013 rev8.indd 3 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Program at a Glance Saturday, December 7, 2013 Monday, December 9, 2013 Tuesday, December 10, 2013 8:00 AM – 3:00 PM Room 319 & 320 12:00 PM – 1:00 PM Room 206 6:45 AM – 8:00 AM Room 220 ACNP Council Meeting CNS Spectrums Field Editor/Deputy Editor CDI Booster Session Meeting 8:00 AM – 5:00 PM Diplomat Ballroom 5 7:00 AM – 8:00 AM Room 207 ACNP Membership Committee Meeting 1:30 PM – 3:00 PM Grand Ballroom ACNP Leadership & Institute Directors Distinguished Lecture: “The Story of Rett 8:00 AM – 8:00 PM Diplomat Ballroom 1 & 2 Syndrome and the Insight it Provides into 7:00 AM – 8:00 AM Room 218 Schizophrenia Prodome Meeting Neuropsychiatric Disorders” CME Institute Executive Directors Meeting 2:00 PM – 4:00 PM Room 208 Mini-Panel Sessions 7:00 AM – 8:30 AM Diplomat Ballroom 4 Neuropsychopharmacology & 3:00 PM – 4:15 PM Diplomat Ballroom 1 & 2 ACNP Education & Training Committee Neuropsychopharmacology Reviews Neuronal Immaturity in Schizophrenia Meeting EIC & Deputy Editors Meeting 4:15 PM – 5:30 PM Diplomat Ballroom 1 & 2 7:00 AM – 8:30 AM Room 203 4:00 PM – 5:00 PM Room 218 Social Processes Initiative in ACNP Membership Advisory Task Force ACNP Website Editors Meeting Neurobiology of the Schizophrenia(s) Meeting 4:00 PM – 5:30 PM Room 202 Panel Sessions ACNP Ethics Committee Meeting 7:00 AM – 8:30 AM Room 316 3:00 PM – 5:30 PM Atlantic Ballroom 1 American Journal of Psychiatry Editorial 5:00 PM – 6:30 PM Room 208 Kicking Over the Traces – Noncatecholic Board Meeting ACNP Publications Committee Meeting Biogenic Amines and Their Receptors Mini-Panel Sessions 6:30 PM – 8:30 PM Great Hall 5 3:00 PM – 5:30 PM Regency Ballroom 2 8:30 AM – 9:45 AM Diplomat Ballroom 1 & 2 ACNP Travel Award Reception Can Biology Inform Treatment Prediction and Biochemical and Behavioral Pharmacology (by invitation only) Selection in Depression? of Synthetic Cathinone Derivatives Found in Psychoactive Bath Salts Products Sunday, December 8, 2013 3:00 PM – 5:30 PM Atlantic Ballroom 2 Autism Spectrum Disorders: From Rare 9:45 AM – 11:00 AM Diplomat Ballroom 1 & 2 8:30 AM – 11:30 AM Regency Ballroom 1 & 2 Chromosomal Abnormalities to Common After the Trauma: Developmental Trajectories Neuropsychopharmacology Reviews Molecular Targets from Childhood to Adult Psychiatric Disorders Plenary: “Frontiers in Discovery and 3:00 PM – 5:30 PM Atlantic Ballroom 3 Neurotherapeutics” Panel Sessions Circuitry Underlying Obsessive-compulsive 8:30 AM – 11:00 AM Regency Ballroom 3 Disorder: Lessons from Deep Brain 11:30 AM – 1:00 PM Room 212 & 213 Augmentation of Antidepressant Response by Stimulation and Ablative Surgery Past Presidents’ Luncheon Autoreceptor-mediated Mechanisms: Clinical Experience and Mechanisms of Action 11:30 AM – 1:00 PM Diplomat Ballroom 5 3:00 PM – 5:30 PM Regency Ballroom 1 ACNP Program Committee Meeting The Role of Inflammation in the Pathophysiology of Mood, Aggressive and 8:30 AM – 11:00 AM Regency Ballroom 2 11:30 AM – 1:00 PM Diplomat Ballroom 4 Medical Disorders: A Deadly Combination Neuroactive Steroids and Oxysterols as ACNP Liaison Committee Meeting Endogenous Modulators of GABA and 3:00 PM – 5:30 PM Regency Ballroom 3 Glutamate Receptors: Basic Mechanisms and 11:30 AM – 1:00 PM Diplomat Ballroom 1 Structural and Functional Brain Changes Therapeutic Implications FNIH Biomarkers Consortium in Young People at Risk for Severe Mental Illness 8:30 AM – 11:00 AM Atlantic Ballroom 1 11:30 AM – 1:00 PM Diplomat Ballroom 2 The Future of Translational Research in Neuropsychopharmacology Editorial Board 5:30 PM – 7:30 PM Great Hall 1-4 Addiction Poster Session I with Reception 1:00 PM – 2:30 PM Regency Ballroom 1 & 2 8:30 AM – 11:00 AM Atlantic Ballroom 2 NIH Institutes Directors’ Briefing Study Groups At the Crossroads of Physics, Physiology, and 7:30 PM – 9:00 PM Regency Ballroom 1 Psychiatry: Rational Design of Noninvasive 2:30 PM – 6:30 PM Regency Ballroom 1 & 2 The Challenges of Designing and Interpreting Neuromodulation Therapies Hot Topics Clinical Trials with Depot Antipsychotics 8:30 AM – 11:00 AM Atlantic Ballroom 3 6:30 PM – 7:30 PM Room 201 & 202 7:30 PM – 9:00 PM Regency Ballroom 2 Nutrition, Neurodevelopment, and Risk Associate Member Reception Mental Illness, Violence and the Gun Control for Schizophrenia and Autism: From (by invitation only) Debate: Evidence, Policy, Privacy and Stigma Epidemiology to Epigenetics 7:00 PM – 9:00 PM Infinity Pool “T” Area – On Behalf of the ACNP Ethics Committee Opening Night Reception 8:30 AM – 11:00 AM Regency Ballroom 1 7:30 PM – 9:00 PM Regency Ballroom 3 Peripheral Immune and Endocrine Pathways New Models of Open Innovation to Monday, December 9, 2013
Recommended publications
  • DFA INVESTMENT DIMENSIONS GROUP INC Form NPORT-P Filed 2021-03-25

    DFA INVESTMENT DIMENSIONS GROUP INC Form NPORT-P Filed 2021-03-25

    SECURITIES AND EXCHANGE COMMISSION FORM NPORT-P Filing Date: 2021-03-25 | Period of Report: 2021-01-31 SEC Accession No. 0001752724-21-062357 (HTML Version on secdatabase.com) FILER DFA INVESTMENT DIMENSIONS GROUP INC Mailing Address Business Address 6300 BEE CAVE ROAD 6300 BEE CAVE ROAD CIK:355437| IRS No.: 363129984 | State of Incorp.:MD | Fiscal Year End: 1031 BUILDING ONE BUILDING ONE Type: NPORT-P | Act: 40 | File No.: 811-03258 | Film No.: 21771544 AUSTIN TX 78746 AUSTIN TX 78746 (512) 306-7400 Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document DFA INVESTMENT DIMENSIONS GROUP INC. FORM N-Q REPORT January 31, 2021 (UNAUDITED) Table of Contents DEFINITIONS OF ABBREVIATIONS AND FOOTNOTES T.A. U.S. Core Equity 2 Portfolio Tax-Managed DFA International Value Portfolio T.A. World ex U.S. Core Equity Portfolio VA U.S. Targeted Value Portfolio VA U.S. Large Value Portfolio VA International Value Portfolio VA International Small Portfolio VA Short-Term Fixed Portfolio VA Global Bond Portfolio VIT Inflation-Protected Securities Portfolio VA Global Moderate Allocation Portfolio U.S. Large Cap Growth Portfolio U.S. Small Cap Growth Portfolio International Large Cap Growth Portfolio International Small Cap Growth Portfolio DFA Social Fixed Income Portfolio DFA Diversified Fixed Income Portfolio U.S. High Relative Profitability Portfolio International High Relative Profitability Portfolio VA Equity Allocation Portfolio DFA MN Municipal Bond Portfolio DFA California Municipal Real Return Portfolio DFA Global Core Plus Fixed Income Portfolio Emerging Markets Sustainability Core 1 Portfolio Emerging Markets Targeted Value Portfolio DFA Global Sustainability Fixed Income Portfolio DFA Oregon Municipal Bond Portfolio NOTES TO FINANCIAL STATEMENTS Organization Security Valuation Financial Instruments Federal Tax Cost Recently Issued Accounting Standards Other Subsequent Event Evaluations Table of Contents TABLE OF CONTENTS CONTINUED THE DFA INVESTMENT TRUST COMPANY SCHEDULES OF INVESTMENTS The U.S.
  • Criminal Restitution Improvement Act of 2006

    Criminal Restitution Improvement Act of 2006

    CRIMINAL RESTITUTION IMPROVEMENT ACT OF 2006 HEARING BEFORE THE SUBCOMMITTEE ON CRIME, TERRORISM, AND HOMELAND SECURITY OF THE COMMITTEE ON THE JUDICIARY HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION ON H.R. 5673 JUNE 13, 2006 Serial No. 109–116 Printed for the use of the Committee on the Judiciary ( Available via the World Wide Web: http://judiciary.house.gov U.S. GOVERNMENT PRINTING OFFICE 28–198 PDF WASHINGTON : 2006 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate 0ct 09 2002 14:44 Aug 15, 2006 Jkt 000000 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 G:\WORK\CRIME\061306\28198.000 HJUD2 PsN: 28198 COMMITTEE ON THE JUDICIARY F. JAMES SENSENBRENNER, JR., Wisconsin, Chairman HENRY J. HYDE, Illinois JOHN CONYERS, JR., Michigan HOWARD COBLE, North Carolina HOWARD L. BERMAN, California LAMAR SMITH, Texas RICK BOUCHER, Virginia ELTON GALLEGLY, California JERROLD NADLER, New York BOB GOODLATTE, Virginia ROBERT C. SCOTT, Virginia STEVE CHABOT, Ohio MELVIN L. WATT, North Carolina DANIEL E. LUNGREN, California ZOE LOFGREN, California WILLIAM L. JENKINS, Tennessee SHEILA JACKSON LEE, Texas CHRIS CANNON, Utah MAXINE WATERS, California SPENCER BACHUS, Alabama MARTIN T. MEEHAN, Massachusetts BOB INGLIS, South Carolina WILLIAM D. DELAHUNT, Massachusetts JOHN N. HOSTETTLER, Indiana ROBERT WEXLER, Florida MARK GREEN, Wisconsin ANTHONY D. WEINER, New York RIC KELLER, Florida ADAM B. SCHIFF, California DARRELL ISSA, California LINDA T. SA´ NCHEZ, California JEFF FLAKE, Arizona CHRIS VAN HOLLEN, Maryland MIKE PENCE, Indiana DEBBIE WASSERMAN SCHULTZ, Florida J.
  • Behavioral and Brain Sciences Plasticity: Implications for Opioid

    Behavioral and Brain Sciences Plasticity: Implications for Opioid

    Behavioral and Brain Sciences http://journals.cambridge.org/BBS Additional services for Behavioral and Brain Sciences: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Behavioral and Brain Sciences / Volume 20 / Issue 03 / September 1997, pp 392 ­ 403 DOI: null, Published online: 08 September 2000 Link to this article: http://journals.cambridge.org/abstract_S0140525X97241488 How to cite this article: Anthony H. Dickenson (1997). Plasticity: Implications for opioid and other pharmacological interventions in specific pain states. Behavioral and Brain Sciences,20, pp 392­403 Request Permissions : Click here Downloaded from http://journals.cambridge.org/BBS, IP address: 144.82.107.43 on 10 Aug 2012 BEHAVIORAL AND BRAIN SCIENCES (1997) 20, 392±403 Printed in the United States of America Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Department of Pharmacology, University College London, London WC1E 6BT, United Kingdom Electronic mail: anthony.dickenson6ucl.ac.uk Abstract: The spinal mechanisms of action of opioids under normal conditions are reasonably well understood. The spinal effects of opioids can be enhanced or reduced depending on pathology and activity in other segmental and nonsegmental pathways. This plasticity will be considered in relation to the control of different pain states using opioids. The complex and contradictory findings on the supraspinal actions of opioids are explicable in terms of heterogeneous descending pathways to different spinal targets using multiple transmitters and receptors ± therefore opioids can both increase and decrease activity in descending pathways.
  • Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands

    Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands

    Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands By Stephanie Nicole Johnson Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Masters in Science. Chairperson: Dr. Thomas E. Prisinzano Dr. Apurba Dutta Dr. Jeffrey P. Krise Date Defended: May 2, 2017 The Thesis Committee for Stephanie Nicole Johnson certifies that this is the approved version of the following thesis: Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands Chairperson: Dr. Thomas E. Prisinzano Date approved: May 4, 2017 ii Abstract The ability of ligands to differentially regulate the activity of signaling pathways coupled to a receptor potentially enables researchers to optimize therapeutically relevant efficacies, while minimizing activity at pathways that lead to adverse effects. Recent studies have demonstrated the functional selectivity of kappa opioid receptor (KOR) ligands acting at KOR expressed by rat peripheral pain sensing neurons. In addition, KOR signaling leading to antinociception and dysphoria occur via different pathways. Based on this information, it can be hypothesized that a functionally selective KOR agonist would allow researchers to optimize signaling pathways leading to antinociception while simultaneously minimizing activity towards pathways that result in dysphoria. In this study, our goal was to alter the structure of U50,488 such that efficacy was maintained for signaling pathways important for antinociception (inhibition of cAMP accumulation) and minimized for signaling pathways that reduce antinociception. Thus, several compounds based on the U50,488 scaffold were designed, synthesized, and evaluated at KORs. Selected analogues were further evaluated for inhibition of cAMP accumulation, activation of extracellular signal-regulated kinase (ERK), and inhibition of calcitonin gene- related peptide release (CGRP).
  • February 2020–Additional Mental Health Related Videos and Articles from Around the Nation

    February 2020–Additional Mental Health Related Videos and Articles from Around the Nation

    February 2020–Additional Mental Health Related Videos and Articles from Around the Nation What schizophrenia does to families — and why the mental health system can’t keep up - A mother, a son and an unraveling mind. From the Magazine ● By Abigail Jones ● Read more » Red Flag law – Colorado Just Used Its New Gun Seizure Law for the First Time – One Day After It Took Effect https://www.washingtonpost.com/nation/2020/01/08/colorado-just-used-its-gun-seizure-law-first-time-one-day- after-it-took- effect/?utm_campaign=post_most&utm_medium=Email&utm_source=Newsletter&wpisrc=nl_most&wpmm=1 Bp Magazine - Bouncing Back Financially After the Holidays - Read more >> Bp Magazine - Deep Sleep Can Rewire the Anxious Brain - Read more >> Stat: This Advocate Wants Mental Health On The Ballot In 2020 - A top mental health and addiction treatment advocate here wants behavioral health on the ballot in 2020. It’s a winning issue, according to Chuck Ingoglia, the president and CEO of the National Council for Behavioral Health, a D.C. nonprofit that represents thousands of community mental health providers. According to a presidential primary poll the organization released last month, large majorities of New Hampshire voters believe the federal government isn’t doing enough to address the nation’s addiction and mental health challenges. (Facher, 12/2) Seattle Times: Amid Serious Violations At Washington’s Private Psychiatric Hospitals, A Regulator Remained On The Sidelines - The patient had been admitted to Smokey Point Behavioral Hospital on a 90-day involuntary commitment order. But when his health-insurance plan sent a team to check on him, some 20 days into his stay, he was gone.
  • Nobel Prizes

    Nobel Prizes

    W W de Herder Heroes in endocrinology: 1–11 3:R94 Review Nobel Prizes Open Access Heroes in endocrinology: Nobel Prizes Correspondence Wouter W de Herder should be addressed to W W de Herder Section of Endocrinology, Department of Internal Medicine, Erasmus MC, ’s Gravendijkwal 230, 3015 CE Rotterdam, Email The Netherlands [email protected] Abstract The Nobel Prize in Physiology or Medicine was first awarded in 1901. Since then, the Nobel Key Words Prizes in Physiology or Medicine, Chemistry and Physics have been awarded to at least 33 " diabetes distinguished researchers who were directly or indirectly involved in research into the field " pituitary of endocrinology. This paper reflects on the life histories, careers and achievements of 11 of " thyroid them: Frederick G Banting, Roger Guillemin, Philip S Hench, Bernardo A Houssay, Edward " adrenal C Kendall, E Theodor Kocher, John J R Macleod, Tadeus Reichstein, Andrew V Schally, Earl " neuroendocrinology W Sutherland, Jr and Rosalyn Yalow. All were eminent scientists, distinguished lecturers and winners of many prizes and awards. Endocrine Connections (2014) 3, R94–R104 Introduction Endocrine Connections Among all the prizes awarded for life achievements in In 1901, the first prize was awarded to the German medical research, the Nobel Prize in Physiology or physiologist Emil A von Behring (3, 4). This award heralded Medicine is considered the most prestigious. the first recognition of extraordinary advances in medicine The Swedish chemist and engineer, Alfred Bernhard that has become the legacy of Nobel’s prescient idea to Nobel (1833–1896), is well known as the inventor of recognise global excellence.
  • Q3 FY 2019-20 Press Release

    Q3 FY 2019-20 Press Release

    Press Release Godfrey Phillips India Limited net profit up to INR 340 Cr in YTD Dec FY’20 New Delhi, February 07, 2020: Godfrey Phillips India Ltd. today reported its result for the third quarter for FY2019-20. The Board of Directors of the Company met today to discuss the performance and shared the copy of the Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended on 31st, December 2019. The Company’s President & Managing Director, Dr. Bina Modi, said, “The Company has performed well despite sectoral challenges during the quarter. We have successfully gained market share and strengthened our position throughout this financial year. I am happy to report a YTD volume growth of 13 % in the domestic market. The International Division registered a remarkable value growth of 34% in exports. The performance is reflective of our commitment towards building value for all our shareholders. We, at Godfrey Phillips India Ltd. have done a phenomenal job in steering the Company towards a growth path. We are on a mission to maximize value for all our stakeholders in a transparent manner. Mr. KK Modi had embarked on this journey and we will continue to build on his legacy.” CEO, Mr. Bhisham Wadhera said, “We reported a profit before tax of INR 450 Cr for the nine months ended on 31st Dec, 2019 which is, approx Rs 140 Cr more than corresponding period last year. Q3 FY 2019-20 has been good with robust growth, and I am very optimistic about the future that lies ahead of us.
  • Gpil) (Bse: 500163; Nse: Godfryphlp)

    Gpil) (Bse: 500163; Nse: Godfryphlp)

    Godfrey Phillips India Limited (GPIL) (BSE: 500163; NSE: GODFRYPHLP) EARNINGS PRESENTATION Q4 & Full Year 2020-21 W E B U I L D US FY21 Highlights Company Tobacco Consumer & Retail Rs. 6,408 Cr. Rs 5,323 Cr. Rs. 354 Cr. Gross Sales Value Domestic Cigarette Gross Sales Value TFS Gross Sales Value Rs. 1,272 Cr. Gross Profit 93 Rs. 597 Cr. TFS stores International Gross Sales Value 19.9% Gross Profit Margin 93% Rs. 121 Cr. Rs. 357 Cr. Chewing Products Gross Sales Value Net Profit Tobacco contribution to Gross sales Value 1 Above values are based on standalone financials 2 Gross Sales Value is inclusive of all applicable indirect taxes 3 Margins are calculated on Gross Sales Value www.godfreyphillips.com 2 Godfrey Phillips Product Portfolio –FY21 Net Sales: Rs. 2,905 Cr Tobacco Non -Tobacco 67% 21% 12% Domestic International Consumer & Retail 2 Chewing Chewing Products Marlboro TFS (24Seven) Tobacco Leaf, Cigarettes & Processed tobacco Confectionary 1 The ratios shown above are based on Net Sales 2 Marlboro is manufactured and distributed under exclusive procurement and supply agreements with Philip Morris International www.godfreyphillips.com 3 Management Perspective “Recovery trend continued to advance into fourth quarter of the current financial year. While the tough market conditions improved over the last few quarters, the residual impact of the adversity continued. In wake of the relatively challenging market conditions, the Company reported Gross Sales Value of Rs. 6,408 Crores and Net Profit of Rs. 357 Crores during FY21. This was made possible by significant efforts and recovery in businesses.
  • Opioids Regulate Cgmp Formationin Cloned Neuroblastoma Cells

    Opioids Regulate Cgmp Formationin Cloned Neuroblastoma Cells

    Proc. NatL. Acad. Sci. USA Vol. 79, pp. 690-694, January 1982 Neurobiology Opioids regulate cGMP formation in cloned neuroblastoma cells (cyclic nucleotides/opiate receptor/desensitization) GERMAINE J. GWYNN AND ERMINIO COSTA* Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. 20032 Communicated by Floyd E. Bloom, October 8, 1981 ABSTRACT Opioid agonists caused a rapid dose-related el- cumulation in rat striatal slices with characteristics that fulfill evation of the cGMP content of N4TG1 murine neuroblastoma the criteria for a specific narcotic action (6). In contrast, the cells. An excellent correlation was found between the rank order decrements in the cGMP content ofcerebellar tissue observed of potency of agonists in stimulating cGMP accumulation and in after morphine administration are probably indirect effects of displacing [3H]etorphine ([H]ETP) bound to intact cells. The nar- opioid receptor stimulation mediated by the modulation of y- cotic antagonists naloxone and diprenorphine failed to increase aminobutyric acid or acetylcholine collateral neuronal loops (7, cGMP content; moreover, in the presence of 5 ,IM naloxone, the 8). A functional role for cGMP in opioid action is further sug- EC50 of ETP increased from w9 nM to >1 ,uM. N4TG1 cells that had been incubated for 20 min with 0.32 ItM ETP and thoroughly gested by the pivotal role that calcium ions play both in regu- washed displayed a marked loss in sensitivity to subsequent ETP lating cGMP formation (for review, see refs. 9, 10) and in me- challenge. This desensitization was characterized by a 40-50% diating the acute and chronic effects ofopioids (for review, see decrease in maximal response and an increase in the apparent Ka refs.
  • David Botstein 2015 Book.Pdf

    David Botstein 2015 Book.Pdf

    Princeton University HONORS FACULTY MEMBERS RECEIVING EMERITUS STATUS May 2015 The biographical sketches were written by colleagues in the departments of those honored. Copyright © 2015 by The Trustees of Princeton University 550275 Contents Faculty Members Receiving Emeritus Status 2015 Steven L. Bernasek .......................3 David Botstein...........................6 Erhan Çinlar ............................8 Caryl Emerson.......................... 11 Christodoulos A. Floudas ................. 15 James L. Gould ......................... 17 Edward John Groth III ...................20 Philip John Holmes ......................23 Paul R. Krugman .......................27 Bede Liu .............................. 31 Alan Eugene Mann ......................33 Joyce Carol Oates .......................36 Clarence Ernest Schutt ...................39 Lee Merrill Silver .......................41 Thomas James Trussell ...................43 Sigurd Wagner .........................46 { 1 } { 2 } David Botstein avid Botstein was educated at Harvard (A.B. 1963) and the D University of Michigan (Ph.D. 1967). He joined the faculty of the Massachusetts Institute of Technology, rising through the ranks from instructor to professor of genetics. In 1987, he moved to Genentech, Inc. as vice president–science, and, in 1990, he joined Stanford University’s School of Medicine, where he was chairman of the Department of Genetics. In July, 2003 he became director of the Lewis-Sigler Institute for Integrative Genomics and the Anthony B. Evnin ’62 Professor of Genomics at Princeton University. David’s research has centered on genetics, especially the use of genetic methods to understand biological functions. His early work in bacterial genetics contributed to the discovery of transposable elements in bacteria and an understanding of their physical structures and genetic properties. In the early 1970s, he turned to budding yeast (Saccharomyces cerevisiae) and devised novel genetic methods to study the functions of the actin and tubulin cytoskeletons.
  • Phd Thesis Project: Pharmacological and Toxicological Investigations of New Psychoactive Substances, Supervised by Prof

    Phd Thesis Project: Pharmacological and Toxicological Investigations of New Psychoactive Substances, Supervised by Prof

    PHARMACOLOGICAL AND TOXICOLOGICAL INVESTIGATIONS OF NEW PSYCHOACTIVE SUBSTANCES Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Dino Lüthi aus Rüderswil, Bern Basel, 2018 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung-Nicht kommerziell 4.0 International Lizenz (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.de). Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Stephan Krähenbühl, Prof. Matthias E. Liechti und Prof. Anne Eckert. Basel, den 26.06.2018 Prof. Martin Spiess Dekan der Philosophisch- Naturwissenschaftlichen Fakultät PHARMACOLOGICAL AND TOXICOLOGICAL INVESTIGATIONS OF NEW PSYCHOACTIVE SUBSTANCES “An adult must make his own decision as to whether or not he should expose himself to a specific drug, be it available by prescription or proscribed by law, by measuring the potential good and bad with his own personal yardstick.” ― Alexander Shulgin, Pihkal: A Chemical Love Story. PREFACE This thesis is split into a pharmacology part and a toxicology part. The pharmacology part consists of investigations on the monoamine transporter and receptor interactions of traditional and newly emerged drugs, mainly stimulants and psychedelics; the toxicology part consists of investigations on mechanisms of hepatocellular toxicity of synthetic cathinones. All research described in this thesis has been published in peer-reviewed journals, and was performed between October 2014 and June 2018 in the Division of Clinical Pharmacology and Toxicology at the Department of Biomedicine of the University Hospital Basel and University of Basel, and partly at the pRED Roche Innovation Center Basel at F.
  • Effect of Taxes and Government Laws on Cigarette Industry in India

    Effect of Taxes and Government Laws on Cigarette Industry in India

    International Journal of Progressive Sciences and Technologies (IJPSAT) ISSN: 2509-0119 Vol. 3 No. 1 June 2016, pp. 66-75 © 2016 International Journals of Sciences and High Technologies http://ijpsat.ijsht-journals.org Effect of Taxes and Government Laws on Cigarette Industry in India Nikhil Patidar 1, Sachet Jain 2 1 Biochemical and Biotechnology, Indian Institute of Technology, Delhi, India 2Textile Technology, Indian Institute of Technology, Delhi, India ABSTRACT : Taxes and Government Laws in any economy play a huge role on the cigarette industry worldwide and hence this paper is an attempt to analyze the effects of the government policies and literacy rates on the cigarette industry in India. Trend of the industry over the past fifteen years is analyzed and the effect of government policies of 2003, 2008 and 2013 is studied using the benchmark analysis via comparison with industrial average. DuPont 5 point ratios are being used to compare the companies with the market trends. Also Regression analysis has been performed to comprehend the relative impact of all the five DuPont ratios on return on equity. The study shows that the policies of 2008 and 2013 has helped the government of India to generate more revenue, resulting in the rise in cigarette prices and hence reduced relative consumption. The policies of 2003 resulted in reduced shareholder’s equity and as the tax increased in the next decade the tax burden ratio also decreased in 2008 and 2013. The study also shows that the operating profit ratio has decreased as the profit to the company has reduced in comparison to the sales made.